



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# بسم الله الرحمن الرحيم



**HANAA ALY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم



# شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



**HANAA ALY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



### يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**HANAA ALY**

**The Effect of Intra-myometrial Methylergonovine Injection  
Versus Placebo on Decreasing Blood Loss During Trans-  
abdominal Myomectomy: A Randomized Controlled  
Interventional Clinical Trial**

*Thesis*

*Submitted for partial fulfillment of the Masters Degree  
in Obstetrics and Gynecology*

*By*

**Aliaa Emadeldin Mohamed Galal Selim**

M.B.B.Ch. – MUST University 2017  
Visitor resident of obstetrics and gynecology at  
Ain Shams University Maternity Hospital

*Under the Supervision of*

**Dr. Ahmed Adel Tharwat**

Assistant Professor of Obstetrics and Gynecology  
Faculty of Medicine – Ain Shams University

**Dr. Aliaa Mohamed Maaty**

Lecturer in Obstetrics and Gynecology  
Faculty of Medicine – Ain Shams University

*Faculty of Medicine  
Ain Shams University*

2020

---

## **Acknowledgement**

*“Always take note of those who support you genuinely.  
Those are the people you should always keep around.”*

*First of all, thanks are all due to **Allah**, for among all his gifts, he has blessed this work until it has reached it's end.*

*My deep appreciation to **Dr. Ahmed Adel Tharwat**, Assistant Professor of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University and **Dr. Aliaa Mohamed Maaty** Lecturer in Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University, for adding a lot to this work by their experience and their keen supervision.*

*Words can't describe how grateful I am to people who supported me through every step in this long journey.*

*To **my beloved family, my close friends who never left my side**, and finally **to the lifelong partner and one of the most talented surgeons I have ever seen, who taught me and stood by my side till I could be the one who I am today.***

*I couldn't have done it without you.*

*For the endless support and love, I can never repay you.*

*A. E. Selim  
December 2020*

---

# List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations .....	i
List of Tables .....	iii
List of Figures .....	iv
Introduction .....	1
Aim of the Work .....	5
<b>Review of Literature</b>	
Chapter (1): Uterine Leiomyoma.....	6
Chapter (2): Management Options .....	21
Chapter (3):Abdominal Myomectomy and techniques to decrease blood loss .....	41
Chapter (4): Methylergonovine .....	67
Patients and Methods .....	77
Results .....	90
Discussion .....	99
Conclusion .....	105
Limitation & Recommendation.....	106
Summary .....	107
References.....	113
Arabic Summary .....	--

## List of Abbreviations

<i>Abbr.</i>	<i>Full-term</i>
<b>2D US</b>	: Two Dimensional Ultrasound.
<b>ABL</b>	: Allowable Blood Loss.
<b>ACOG</b>	: American College of Obstetricians and Gynecologists.
<b>ALT</b>	: Alanine Transferase.
<b>AUB</b>	: Abnormal Uterine Bleeding.
<b>BMD</b>	: Bone Mineral Density.
<b>BMI</b>	: Body Mass Index.
<b>CI</b>	: Confidence Interval.
<b>COCs</b>	: Combined Oral Contraceptives..
<b>EBV</b>	: Estimated Blood Volume.
<b>ESHRE</b>	: European Society for Human Reproduction and Embryology.
<b>FDA</b>	: Food and Drug Administration.
<b>FIGO</b>	: Fédération Internationale de Gynécologie et d'Obstétrique.
<b>FMDG</b>	: FIGO Menstrual Disorders Group.
<b>FSH</b>	: Follicle-Stimulating Hormone.
<b>GnRH</b>	: Gonadotrophin Releasing Hormone.
<b>Hb</b>	: Hemoglobin.
<b>HBV</b>	: Hepatitis B Virus.
<b>HCV</b>	: Hepatitis C Virus.
<b>H<sub>f</sub></b>	: Final Lowest Acceptable Hematocrit.
<b>H<sub>i</sub></b>	: Initial Hematocrit.
<b>IM</b>	: Intramuscular.
<b>INR</b>	: International Normalized Ratio.
<b>IUS</b>	: Intrauterine System.
<b>IV</b>	: Intravenous.
<b>LH</b>	: Leuteinizing Hormone.
<b>LM</b>	: Laparoscopic Myomectomy

<b>LSD</b>	: Lysergic Acid Diethylamide
<b>LUAO</b>	: Laparoscopic Uterine Artery Occlusion.
<b>M.W</b>	: Molecular Weight.
<b>Mcg</b>	: Micrograms.
<b>MRgFUS</b>	: Magnetic Resonance-guided Focused-Ultrasound Surgery.
<b>MRI</b>	: Magnetic Resonance Imaging.
<b>NG</b>	: Nulligravida.
<b>NSAIDs</b>	: Nonsteroidal Anti-inflammatory Drugs.
<b>OCs</b>	: Oral Contraceptives.
<b>PALM-COEIN</b>	: Polyp, Adenomyosis, Leiomyoma, and Malignancy – Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified..
<b>PKA</b>	: Protein Kinase A.
<b>PRM</b>	: Progesterone Receptor Modulators.
<b>PT</b>	: Prothrombin Time.
<b>PTHrP</b>	: Parathyroid hormone related protein.
<b>PTT</b>	: Partial Thromboplastin Time.
<b>PV examination</b>	: Pervaginal Examination.
<b>RBCs</b>	: Red blood Cells.
<b>rHuEPO</b>	: Recombinant Human Erythropoietin.
<b>SOGC</b>	: Society of Obstetricians and Gynaecologists.
<b>UAE</b>	: Uterine Artery Embolization.
<b>UFE</b>	: Uterine Fibroid Embolization.
<b>USA</b>	: United States of America.
<b>Vs</b>	: Versus.



## List of Tables

<i>Tables No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table (01):</b>	Randomization table .....	81
<b>Table (02):</b>	Demographic characteristics among the studied groups .....	91
<b>Table (03):</b>	Myoma number and size among the studied groups .....	91
<b>Table (04):</b>	Operation time (minutes) among the studied groups .....	92
<b>Table (05):</b>	Estimated intraoperative blood loss (mL) among the studied groups .....	93
<b>Table (06):</b>	Hemoglobin (gm/dL) among the studied groups .....	94
<b>Table (07):</b>	Hematocrit (%) among the studied groups .....	95
<b>Table (08):</b>	Blood transfusion among the studied groups .....	96
<b>Table (09):</b>	Blood transfusion units among the studied groups .....	97
<b>Table (10):</b>	Conversion to hysterectomy among the studied groups .....	98

## List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure (01):</b>	Fibroid location: epidemiology, clinical manifestations, diagnosis and natural history of fibroids.....	12
<b>Figure (02):</b>	Hystroscopic classification of submucous fibroids .....	13
<b>Figure (03):</b>	Figo classification system (PALM-COEIN) for causes of abnormal uterine bleeding, .....	14
<b>Figure (04):</b>	Figo classification system (PALM-COEIN) for causes of abnormal uterine bleeding .....	15
<b>Figure (05):</b>	The Management of Uterine Leiomyomas.....	40
<b>Figure (06):</b>	Altered uterine vascular patterns by multiple myomas .....	48
<b>Figure (07):</b>	Pericervical tourniquet in transabdominal myomectomy.....	53
<b>Figure (08):</b>	Vertical incision into anterior uterine cavity in abdominal myomectomy .....	56
<b>Figure (09):</b>	Placement of Allis clamp for traction on myoma during myomectomy, .....	58
<b>Figure (10):</b>	Towel clamp on myoma during myomectomy .....	58
<b>Figure (11):</b>	Bonney myomectomy clamp.....	59
<b>Figure (12):</b>	Myoma dissection .....	59
<b>Figure (13):</b>	Closure of uterine defect .....	60
<b>Figure (14):</b>	Closure of outer myometrium .....	60
<b>Figure (15):</b>	Serosal repair after myomectomy .....	61
<b>Figure (16):</b>	Structure of Methylergonovine .....	68
<b>Figure (17):</b>	SF-2012 digital scale.....	87
<b>Figure (18):</b>	Flow chart of the studied cases .....	90
<b>Figure (19):</b>	Operation time among the studied groups .....	92
<b>Figure (20):</b>	Estimated intraoperative blood loss among the studied groups .....	93
<b>Figure (21):</b>	Hemoglobin drop among the studied groups .....	94
<b>Figure (22):</b>	Hematocrit reduction among the studied groups .....	95
<b>Figure (23):</b>	Blood transfusion among the studied groups.....	96
<b>Figure (24):</b>	Blood transfusion units among the studied groups .....	97
<b>Figure (25):</b>	Conversion to hysterectomy among the studied groups .....	98

## Introduction

Uterine leiomyomas are tumors of the myometrium that have a prevalence as high as 70% to 80% at the age of 50 (*Okolo et al., 2008*), the etiology and prevalence seem to vary with a number of factors including age, race, and possibly geographic location. Prevalence in the United States is almost 40% in white patients and more than 60% in women of African descent in the same age group (*Parker, 2007*).

Leiomyomas are listed as the diagnosis for about 39% of the approximately 600,000 hysterectomies performed each year in the United States (*Zimmermann et al., 2012*).

These benign tumors, are usually asymptomatic, and may be only detectable through ultrasound examination, or associated with a number of clinical issues including abnormal uterine bleeding (AUB) especially heavy menstrual bleeding (HMB), infertility, recurrent pregnancy loss, and complaints related to the impact of the enlarged uterus on adjacent structures in the pelvis, which are often referred to as “bulk” symptoms. It is generally perceived that the symptoms of HMB, infertility, and recurrent pregnancy loss largely occur as a result of lesions that distort the endometrial cavity that are therefore adjacent to the endometrium and

consequently referred to as submucous leiomyomas (*Zimmermann et al., 2012*).

Treatment options for leiomyoma vary; treatment strategies are typically individualized based on the severity of the symptoms, the size and location of the leiomyoma lesions, the patient's age and their chronological proximity to menopause, and the patient's desire for future fertility. The usual goal of therapy is the relief of the symptoms. The treatment options range from the use of acupuncture (ancient Chinese method) to the total removal of the uterus and its myoma contents (hysterectomy) (*American College of Obstetricians and Gynecologists, 2008*).

Treatment of fibroids should be individualized, and symptomatology may be a decisive factor in whether or not a fibroid is removed. Myomectomy remains the gold standard for treatment for patients who wish to preserve their uteri and desire future pregnancy. The procedure can be accomplished by either laparotomy (through an incision into the abdomen) or laparoscopically (*William et al., 2013*).

The presence of leiomyomas in the uterus distorts normal vascular architecture, thus, the arcuate arteries may run in any axis, rather than transversely, therefore, either

vertical or transverse incisions during myomectomy may transect these vessels and increase blood loss during the procedure (*Discepolo et al., 2007*).

Many interventions have been performed to reduce bleeding during myomectomy. According to (*Kongnyuy et al., 2011*) four categories of interventions can be identified:

- *Interventions on uterine arteries:* such as uterine artery embolization (*Dumousset et al., 2008*), pericervical mechanical tourniquet (*Helal et al., 2010*), vasopressin (natural or synthetic) (*Tulandi et al., 1996*) and (*Lurie and Mamet 2000*) a vasoconstrictive solution of bupivacaine plus epinephrine (*Zullo et al., 2004*) and bilateral uterine artery ligation (*Sapmaz and Celik 2003*).
- *Utero-tonics:* such as prostaglandins, misoprostol and, dinoprostone (*Abdel-Hafeez et al., 2015*), sytocinon, methergine, carboprost (*Agostini et al., 2005*), and more recently ascorbic acid and tranexamic acid (*Lee et al., 2016*).
- *Myoma dissection techniques:* which include fibroid enucleation by morcellation (*Sinha et al., 2005*) and the use of chemical dissectors such as sodium-2-mercaptoethane sulphonate (mesna) (*Benassi et al., 2000*).

- Pharmacologic *manipulation of the coagulation cascade*: with antifibrinolytic agents such as tranexamic acid (*Caglar et al., 2008*) and gelatin-thrombin haemostatic sealant (*Raga et al., 2009*).

## **Aim of the Work**

**T**he aim of the current study is to compare the efficacy of intra-myometrial methylergonovine injection and placebo injection on reducing blood loss during trans-abdominal myomectomy.